Synairgen plc (AIM: SNG)

Market Cap	9.24M
Revenue (ttm)	n/a
Net Income (ttm)	-6.92M
Shares Out	201.37M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,107
Open	4.260
Previous Close	4.620
Day's Range	4.260 - 4.489
52-Week Range	3.000 - 11.000
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 27, 2024

About Synairgen

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 36
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: SNG